Questionnaire

1. In patients with T1DM and using AID systems, AI-enabled adaptive behavioural control has been demonstrated to improve TIR beyond the ceiling of AID systems alone.

2. Pancreatic islet AAbs that can identify stage 2 autoimmune T1DM prior to the onset of T1DM symptoms include:

3. Among features that are integral to effective T1DM screening programmes are:

4. Compared with family history-targeted T1DM screening, a Canadian study demonstrated that population-based T1DM screening was more expensive and detected fewer T1DM cases.

5. The current gold standard metabolic test for accurately identifying stage of T1DM is:

6. In terms of predicting the development of stage 3 T1DM:

7. In children who are pancreatic islet AAb-positive, a 40% risk of progression to T1DM within the next year has been associated with TA 7.8mmol/l:

8. Even in the era of technological innovations such as CGM, there is a persistent burden of severe hypoglycaemia and IAH among people with T1DM.

9. Impaired awareness of hypoglycaemia predicts severe hypoglycaemia despite CGM use in patients with:

10. Behaviours that have been associated with increased severe hypoglycaemia in patients with T1DM or insulin-treated T2DM include:

11. In patients with T1DM or insulin-treated T2DM and using CGM, a very low risk of severe hypoglycaemia correlates with TBR:

12. According to the Diabetes Technological Society, GRI is:

13. The glycaemic risk index (GRI) is composed of which of the following metrics.

14. Compared with SMBG at 16 and 32 weeks in FreeDM2 participants with suboptimally controlled T2DM treated with basal insulin, participants using CGM demonstrated significant improvements in:

15. A post hoc analysis of the Soli-D study demonstrated that the proportion of participants achieving the composite endpoint of HbA_1c ≤7% with no weight gain was: